Endo Whistleblower Gets 24% Cut Of $140M FCA Deal
By John Kennedy · July 16, 2015, 6:03 PM EDT
The whistleblower who alerted the government to Endo Pharmaceuticals Inc.'s off-label marketing of the pain-relief patch Lidoderm won 24 percent of a $140 million False Claims Act settlement Wednesday, with a...
To view the full article, register now.